UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study

Obesity (Silver Spring, Md.), 2012-07, Vol.20 (7), p.1426-1436

2012

Volltextzugriff (PDF)

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

The New England journal of medicine, 2010-07, Vol.363 (3), p.245-256

2010

Volltextzugriff (PDF)

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

The journal of clinical endocrinology and metabolism, 2011-10, Vol.96 (10), p.3067-3077

2011

Volltextzugriff (PDF)

Effect of Anti-IgE Therapy in Patients with Peanut Allergy

The New England journal of medicine, 2003-03, Vol.348 (11), p.986-993

2003

Volltextzugriff (PDF)

Antiretroviral Activity of the Anti-CD4 Monoclonal Antibody TNX-355 in Patients Infected with HIV Type 1

The Journal of infectious diseases, 2004-01, Vol.189 (2), p.286-291

2004

Volltextzugriff (PDF)

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Annals of the rheumatic diseases, 2018-06, Vol.77 (6), p.883-889

2018

Volltextzugriff (PDF)

Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential

Pharmacology & therapeutics (Oxford), 2020-01, Vol.205, p.107417, Article 107417

2020

Volltextzugriff (PDF)

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

The New England journal of medicine, 2010-07, Vol.363 (3), p.245-256

2010

Volltextzugriff (PDF)

Adiabatic invariance and its application to Wien's complete displacement law of blackbody radiation

American journal of physics, 2024-02, Vol.92 (2), p.132-139

2024

Volltextzugriff (PDF)

Lorcaserin for Smoking Cessation and Associated Weight Gain: Randomized 12-Week Clinical Trial

Nicotine & tobacco research, 2017-08, Vol.19 (8), p.944-951

2017

Volltextzugriff (PDF)

Lorcaserin (APD356), a Selective 5‐HT2C Agonist, Reduces Body Weight in Obese Men and Women

Obesity (Silver Spring, Md.), 2009-03, Vol.17 (3), p.494-503

2009

Volltextzugriff (PDF)

Effects of lorcaserin on pre‐existing valvulopathy: A pooled analysis of phase 3 trials

Obesity (Silver Spring, Md.), 2017-01, Vol.25 (1), p.39-44

2017

Volltextzugriff (PDF)

Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight‐loss outcomes

Obesity (Silver Spring, Md.), 2014-10, Vol.22 (10), p.2137-2146

2014

Volltextzugriff (PDF)

Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials

Circulation. Cardiovascular imaging, 2013-07, Vol.6 (4), p.560-567

2013

Volltextzugriff (PDF)

A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis

Journal of rheumatology, 2002-03, Vol.29 (3), p.447

2002

Volltextzugriff (PDF)

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

Gastroenterology (New York, N.Y. 1943), 1998-06, Vol.114 (6), p.1133-1142

1998

Volltextzugriff (PDF)

Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection

Transplantation, 2004-09, Vol.78 (6), p.858-863

2004

Volltextzugriff (PDF)

Lorcaserin (APD356), a Selective 5‐HT 2C Agonist, Reduces Body Weight in Obese Men and Women

Obesity (Silver Spring, Md.), 2012-09, Vol.17 (3), p.494-503

2012

Volltextzugriff (PDF)

Response to “Effect of anti-IgE therapy in patients with food allergy”

Annals of allergy, asthma, & immunology, 2003-12, Vol.91 (6), p.515-517

2003

Volltextzugriff (PDF)

Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)

The Journal of pharmacology and experimental therapeutics, 1997-09, Vol.282 (3), p.1173

1997

Volltextzugriff (PDF)

Making sense of antisense

Canadian journal of gastroenterology, 1999-11, Vol.13 (9), p.745-751

1999

Volltextzugriff (PDF)

New approaches for the treatment of anaphylaxis

Novartis Foundation symposium, 2004, Vol.257, p.248

2004

Volltextzugriff (PDF)

Erratum for: Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight‐loss outcomes

Obesity (Silver Spring, Md.), 2014-12, Vol.22 (12), p.2641-2641

2014

Volltextzugriff (PDF)

Lorcaserin (APD356), a Selective 5-HT Agonist, Reduces Body Weight in Obese Men and Women

Obesity (Silver Spring, Md.), 2009-03, Vol.17 (3), p.494-503

2009

Volltextzugriff (PDF)

Endothelial cells enhance the human pokeweed mitogen lymphocyte response

Journal of leukocyte biology, 1985-03, Vol.37 (3), p.305-317

1985

Volltextzugriff (PDF)

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(76)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(98)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(40)
Humans
(39)
Female
(26)
Male
(25)
Adult
(24)
Middle Aged
(24)
Aged
(17)
Biological And Medical Sciences
(16)
Double-Blind Method
(16)
Physical Sciences
(13)
Medical Sciences
(12)
Adolescent
(11)
Physics
(10)
Animals
(9)
Obesity - Drug Therapy
(8)
Benzazepines - Therapeutic Use
(7)
Fundamental And Applied Biological Sciences. Psychology
(7)
Obesity
(7)
Technology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

Effect of Anti-IgE Therapy in Patients with Peanut Allergy

Antiretroviral Activity of the Anti-CD4 Monoclonal Antibody TNX-355 in Patients Infected with HIV Type 1

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

Adiabatic invariance and its application to Wien's complete displacement law of blackbody radiation

Lorcaserin for Smoking Cessation and Associated Weight Gain: Randomized 12-Week Clinical Trial

Lorcaserin (APD356), a Selective 5‐HT2C Agonist, Reduces Body Weight in Obese Men and Women

Effects of lorcaserin on pre‐existing valvulopathy: A pooled analysis of phase 3 trials

Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight‐loss outcomes

Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials

A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection

Lorcaserin (APD356), a Selective 5‐HT 2C Agonist, Reduces Body Weight in Obese Men and Women

Response to “Effect of anti-IgE therapy in patients with food allergy”

Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)

Making sense of antisense

New approaches for the treatment of anaphylaxis

Erratum for: Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight‐loss outcomes

Lorcaserin (APD356), a Selective 5-HT Agonist, Reduces Body Weight in Obese Men and Women

Endothelial cells enhance the human pokeweed mitogen lymphocyte response

Suchergebnisse filtern